GT201500328A - Suplemento de hierro - Google Patents

Suplemento de hierro

Info

Publication number
GT201500328A
GT201500328A GT201500328A GT201500328A GT201500328A GT 201500328 A GT201500328 A GT 201500328A GT 201500328 A GT201500328 A GT 201500328A GT 201500328 A GT201500328 A GT 201500328A GT 201500328 A GT201500328 A GT 201500328A
Authority
GT
Guatemala
Prior art keywords
iron
component
cinc
complexes
agent
Prior art date
Application number
GT201500328A
Other languages
English (en)
Inventor
David Bortz Jonathan
Original Assignee
Amip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amip Llc filed Critical Amip Llc
Publication of GT201500328A publication Critical patent/GT201500328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

UN SISTEMA DE DOSIFICACIÓN PARA SUMINISTRAR EN FORMA ORAL QUE COMPRENDE (A) HIERRO EN FORMA DE UNO O MÁS GRADOS, COMPUESTOS Y/O COMPLEJOS DE HIERRO FISIOLÓGICAMENTE ACEPTABLES, Y (B) UN AGENTE PARA MITIGAR UNO O MÁS EFECTOS GASTROINTESTINALES ADVERSOS DEL HIERRO NO ABSORBIDO, DONDE DICHO AGENTE COMPRENDE UNO DE: UN COMPONENTE DE CINC Y UN COMPONENTE QUELANTE O AMBOS, DONDE SI DICHO COMPONENTE DE CINC ESTÁ PRESENTE COMPRENDE UNO O MÁS COMPUESTOS Y/O COMPLEJOS DE CINC FISIOLÓGICAMENTE ACEPTABLES, Y DONDE SI DICHO COMPONENTE QUELANTE ESTÁ PRESENTE COMPRENDE UN COMPUESTO DE ION-QUELANTE FORMULADO DE MANERA QUE SE LIBERE EN UNA PORCIÓN DISTAL RESPECTO DEL SITIO DE ABSORCIÓN PRIMARIO DEL HIERRO EN EL DUODENOA.
GT201500328A 2013-06-06 2015-11-20 Suplemento de hierro GT201500328A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361831879P 2013-06-06 2013-06-06

Publications (1)

Publication Number Publication Date
GT201500328A true GT201500328A (es) 2017-12-14

Family

ID=52005976

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500328A GT201500328A (es) 2013-06-06 2015-11-20 Suplemento de hierro

Country Status (12)

Country Link
US (2) US11331287B2 (es)
EP (1) EP3003328B1 (es)
AU (1) AU2014275307B2 (es)
BR (1) BR112015029468A8 (es)
CA (1) CA2913413C (es)
CR (1) CR20150665A (es)
ES (1) ES2895044T3 (es)
GT (1) GT201500328A (es)
MX (1) MX2015016660A (es)
PL (1) PL3003328T3 (es)
WO (1) WO2014197250A1 (es)
ZA (1) ZA201508363B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10555531B2 (en) 2015-08-11 2020-02-11 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
US11083738B2 (en) * 2017-09-28 2021-08-10 Natals, Inc. Dietary nutrient compositions
MA50201A (fr) 2017-10-25 2021-04-28 Chiesi Farm Spa Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
US20230321061A1 (en) * 2022-04-11 2023-10-12 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US20230321060A1 (en) * 2022-04-11 2023-10-12 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91047A (en) 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5516925A (en) 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
US7160855B2 (en) 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
US20060134227A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
CN1965697A (zh) 2005-11-15 2007-05-23 王健柏 营养补血保健饮用制品
US8007846B2 (en) 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
WO2009032699A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2010136839A1 (en) 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
CN101744120B (zh) 2009-12-25 2012-04-11 河北农业大学 乳仔猪微量元素预混料
CN102318764B (zh) 2011-08-30 2014-04-02 武汉天龙饲料有限公司 一种无抗仔猪教槽料及其制备方法
WO2013044246A1 (en) 2011-09-22 2013-03-28 Amip Buffered upper gi absorption promoter

Also Published As

Publication number Publication date
WO2014197250A1 (en) 2014-12-11
ES2895044T3 (es) 2022-02-17
BR112015029468A2 (pt) 2017-07-25
CA2913413C (en) 2021-11-23
PL3003328T3 (pl) 2022-01-24
AU2014275307A1 (en) 2015-12-10
CA2913413A1 (en) 2014-12-11
CR20150665A (es) 2016-02-24
US20140364491A1 (en) 2014-12-11
MX2015016660A (es) 2016-07-26
EP3003328B1 (en) 2021-07-28
BR112015029468A8 (pt) 2020-03-17
ZA201508363B (en) 2017-09-27
AU2014275307B2 (en) 2017-06-15
EP3003328A1 (en) 2016-04-13
US11331287B2 (en) 2022-05-17
US20220233476A1 (en) 2022-07-28
EP3003328A4 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
GT201500328A (es) Suplemento de hierro
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2016002971A1 (es) Combinación.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
MY196173A (en) Cot Modulators And Methods Of Use Thereof
BR112016017690A2 (pt) Tratamentos para acne resistente
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
CL2016002311A1 (es) Una composición refractaria para reparación de revestimiento que comprende agregado, polímero, resina; y cemento.
GT201200284A (es) Composición farmacéutica
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2013002585A1 (es) Cierre para un recipiente contenedor de un producto, comprendiendo el cierre de un elemento de metraial polimerico que comprende un agente de liberacion de oxidante cuya cantidad esta en una relacion porcentual en peso(0,01%-10%) dw pwso del elemeto de matreila polimerico; y procedimiento asociado.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
BR112015027824A2 (pt) composições de vitamina e em pó
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2015000848A1 (es) Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12).
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
BR112015015857A2 (pt) composição tópica e método de melhorar a microcirculação da pele
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.